Iltamiocel clinical trials
Also written AMDC-USR.
How each study uses iltamiocel is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2013 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 2 |
| 2015 | 1 |
| 2019 | 1 |
| 2024 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1, 1 in phase 3
Studies that test iltamiocel, phase 3 first.
- Dec 2026Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric InjuryPhase 3 · Cook MyoSite
Studies
Open first, then newest update. How each study uses iltamiocel is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress IncontinenceActive, not recruitingPhase 3Cook MyoSiteNCT03104517Written as AMDC-USR (iltamiocel)
- Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females With Obstetric InjuryActive, not recruitingPhase 3Cook MyoSiteNCT05776277Written as Iltamiocel
- Japanese Bridging Study of Autologous Muscle Derived Cells Compared to Placebo for Female Urinary Sphincter Repair(JPN1)WithdrawnPhase 3Cook MyoSiteNCT03997318Written as AMDC-USR
- Autologous Cell Therapy for Treatment of Fecal IncontinenceCompletedPhase 1/2Cook MyoSiteNCT01600755Written as Iltamiocel
- Autologous Muscle Derived Cells for Female Urinary Sphincter RepairCompletedPhase 3Cook MyoSiteNCT01893138Written as Iltamiocel
- Autologous Cell Therapy for Stress Urinary Incontinence in Males Following Prostate SurgeryCompletedPhase 1/2Cook MyoSiteNCT02291432Written as autologous muscle-derived cells (AMDC)
- Autologous Muscle Derived Cells Female Stress Urinary Incontinence Clinical StudyCompletedPhase 3Cook MyoSiteNCT01382602Written as AMDC-USR
Codes
What other systems call iltamiocel · ClinicalTrials.gg INT017710
- UNII (FDA) QTA2A5N6BEILTAMIOCELOne source FDA
- NCI Thesaurus C177094IltamiocelOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | QTA2A5N6BE | ILTAMIOCEL | One source FDA |
| NCI Thesaurus | C177094 | Iltamiocel | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.